Drugs / IMMH-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04343859 | May 2020 → Dec 2024 | cancer | Tianjin Chasesun Pharmaceutical Co., LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMMH-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04343859 ↗ |
| Action | Inhibit | “IMMH-010 is a prodrug of YPD-29B, which is a novel PD-L1 inhibitor.” PMID 34234673 ↗ Jun 2021 |
| Modality | Small molecule | — CHEMBL5095184 ↗ |